Regulates CDK7, the catalytic subunit of the CDK- activating kinase (CAK) enzymatic complex. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminus domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Involved in cell cycle control and in RNA transcription by RNA polymerase II. Its expression and activity are constant throughout the cell cycle. Associates primarily with CDK7 and MAT1 to form the CAK complex. CAK can further associate with the core-TFIIH to form the TFIIH basal transcription factor. Belongs to the cyclin family. Cyclin C subfamily. Note: This description may include information from UniProtKB.
Protein type: Cell cycle regulation
Chromosomal Location of Human Ortholog: 5q13.3-q14
Molecular Function: RNA polymerase subunit kinase activity; DNA-dependent ATPase activity; protein binding; cyclin-dependent protein kinase regulator activity; protein kinase binding
Biological Process: transcription from RNA polymerase II promoter; transcription initiation from RNA polymerase II promoter; positive regulation of cyclin-dependent protein kinase activity; viral reproduction; positive regulation of viral transcription; transcription from RNA polymerase I promoter; RNA elongation from RNA polymerase I promoter; DNA repair; termination of RNA polymerase I transcription; protein amino acid phosphorylation; regulation of gene expression, epigenetic; mRNA capping; nucleotide-excision repair; negative regulation of gene expression, epigenetic; transcription-coupled nucleotide-excision repair; RNA elongation from RNA polymerase II promoter; gene expression; nucleotide-excision repair, DNA damage removal; positive regulation of transcription from RNA polymerase II promoter; mitotic cell cycle; G2/M transition of mitotic cell cycle; transcription initiation from RNA polymerase I promoter; G1/S transition of mitotic cell cycle
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.